ArticleFrontiers in endocrinology2026
BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: BRAF V600E mutation is the most common and clinically significant genetic alteration in advanced thyroid cancers. This study provides real-world experience with BRAF and MEK inhibitors other than dabrafenib and trametinib in the treatment of advanced thyroid cancers harboring this mutation. Methods: A case series of four patients with advanced thyroid cancer (three papillary and one anaplastic) treated with various BRAF and MEK inhibitors. All patients had confirmed BRAF V600E mutation. Results: Among three patients treated with BRAF/MEK inhibitors for radioiodine refractory metastatic PTC, and one patient with ATC, all (100%) demonstrated a partial response (PR) during therapy, yielding an overall response rate (ORR) of 100%. Stable disease was observed in multiple treatment phases, contributing to a high overall disease control rate. Three patients had disease-related death, while one remained under treatment at last follow-up. The course of treatment was complicated by significant toxicities, leading to dose reductions or treatment discontinuations. Despite initial responses, all cases eventually progressed, necessitating sequential treatment strategies. Overall survival ranged from 6.0 to 25.3 months, with a median follow-up of 18.3 months since the initiation of BRAF and MEK inhibitors. Conclusions: This case series highlights the potential benefits and challenges of targeted therapies in advanced thyroid cancer. While BRAF and MEK inhibitors offer new treatment options, toxicity management and the development of resistance remain significant hurdles. The limited FDA-approved options for BRAF V600E-positive thyroid cancer compared to melanoma underscore the need for further research to optimize and expand treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.